Imran Talat: insider trades.
Imran Talat reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($25K) and 1 sale ($11K), across 1 company.
- Transactions
- 9
- Purchases (P)
- 1
- Sales (S)
- 1
- Companies
- 1
- Name as filed
- Imran Talat
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | Director, Officer · Chief Executive Officer | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-27 | Rani Therapeutics Holdings, Inc. | F | 7,928 | $0.76 | 461,808 | Form 4 |
| 2026-07-17 | Rani Therapeutics Holdings, Inc. | P | 35,000 | $0.72 | 469,736 | Form 4 |
| 2026-06-27 | Rani Therapeutics Holdings, Inc. | F | 7,927 | $0.74 | 434,736 | Form 4 |
| 2026-03-27 | Rani Therapeutics Holdings, Inc. | F | 9,099 | $0.81 | 442,663 | Form 4 |
| 2026-03-22 | Rani Therapeutics Holdings, Inc. | F | 8,916 | $1.13 | 451,762 | Form 4 |
| 2025-12-27 | Rani Therapeutics Holdings, Inc. | F | 7,906 | $1.4 | 460,678 | Form 4 |
| 2025-09-27 | Rani Therapeutics Holdings, Inc. | F | 9,077 | $0.48 | 468,584 | Form 4 |
| 2025-06-27 | Rani Therapeutics Holdings, Inc. | F | 9,076 | $0.55 | 477,661 | Form 4 |
| 2024-12-27 | Rani Therapeutics Holdings, Inc. | S | 8,014 | $1.41 | 486,737 | Form 4 |
Questions
What stock did Imran Talat buy or sell?
Imran Talat reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($25K) and 1 sale ($11K), across 1 company.
Is Imran Talat the same person as other filers with this name?
This page covers SEC CIK 1869579 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/imran-talat-1869579.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.